Top-News
Biotechnologie USA

4D Molecular Therapeutics Aktie

Aktie
WKN:  ISIN:  US35104E1001 US-Symbol:  FDMT
6,2701 €
-0,2388 €
-3,66%
6,58 $ 19:29:22 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
41,86 Mio.
Marktkapitalisierung *
282,02 Mio. €
Streubesitz
-19,15%
Index-Zugehörigkeit
-
*Stand: 19.05.2023

4D Molecular Therapeutics News

26.08.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT PR Newswire
17.08.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT PR Newswire
09.08.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT PR Newswire
22.07.24 - PR Newswire
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm PR Newswire
06.02.24 - PR Newswire
Thinking about trading options or stock in C3.ai, Meta Platforms, 4D Molecular Therapeutics, Li Auto, or Varonis Systems?
Thinking about trading options or stock in C3.ai, Meta Platforms, 4D Molecular Therapeutics, Li Auto, or Varonis Systems? PR Newswire
05.02.24 - PR Newswire
Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram?
Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram? PR Newswire
10.07.23 - PR Newswire
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets PR Newswire
15.11.22 - PR Newswire
Thinking about buying stock in Azenta, Shoals Technologies, Sea, Lufax, or 4D Molecular Therapeutics?
Thinking about buying stock in Azenta, Shoals Technologies, Sea, Lufax, or 4D Molecular Therapeutics? PR Newswire

Newssuche

Videos

newspaper
13:40 Uhr
TRADING Insights Webinar vom 12.12.24
Themen: Aktienmarkt-​Entwicklung, Soft-​Commodities, wie Baumwolle, Kakao, Orangensaft, aber auch die ... Mehr »